ClinicalTrials.gg
TerminatedNCT04142658Updated Mar 20, 2024Results posted

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

A Phase 3 interventional study of Apixaban 5 MG and Apixaban 2.5 MG in Aortic Valve Disease, Aortic Valve Stenosis and Aortic Valve Failure, sponsored by Artivion Inc.. Terminated at 62 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-20.

Primary conditionAortic Valve StenosisRegistry: Aortic Valve DiseaseReclassifiedWhy we changed it
Registry
Aortic Valve Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Valve Stenosis
Why
  1. The study's listed conditions name Aortic Valve Stenosis, a narrower term within Aortic Valve Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Artivion Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Safety

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
863
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Aortic Valve Stenosis with a site in United States — 44 open to participants now, 68 under way, 3 of them phase 3. Aortic Valve Stenosis · United States.

Enrollment
30th of 125
863 · median 172
Started
2020
with 8 others
Phase 3
5 of 189
2 open now
Registered
118th of 189
by date

Among the 189 studies in Aortic Valve Stenosis with a site in United States, this one is the 30th largest by enrollment of the 125 interventional ones that give a count, is one of 9 that started in 2020, is one of 5 in phase 3, and was the 118th registered.

Aortic Valve Stenosis

1,026 studies on the registry are indexed under Aortic Valve Stenosis; 294 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

44 of the 189 studies in Aortic Valve Stenosis with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Aortic Valve Stenosis with a site in United States, or all of them as a file.
02

Study summary

Currently, warfarin is the only approved anticoagulation for patients with mechanical valves. The purpose of this study is to determine if participants with an On-X Prosthetic Heart Valve / On-X aortic valve can be maintained safely and effectively on apixaban. Both the On-X aortic valve and apixaban have been approved for use by the US Food and Drug Administration (FDA) but they have not been approved to be used together.

Read the detailed description

There is an unmet clinical need for an alternative to warfarin, such as a direct oral anticoagulant (DOAC), as anticoagulation in participants with an aortic mechanical prosthetic valve. Some participants may be genetically hyper- or hypo-responsive to warfarin, which makes management difficult. Another small group of participants is allergic to warfarin. A much larger group of participants has difficulty maintaining warfarin control due to dietary and drug interactions. Finally, the requirement for routine blood testing makes people reluctant to take warfarin. All of these factors drive younger participants in need of aortic valve replacement (AVR) toward selection of a tissue valve instead of a mechanical valve. Despite multiple studies (randomized, matched and risk adjusted) that show that tissue valves are associated with worse outcomes, younger participants choose this type of valve to avoid warfarin. In addition, multiple clinical studies have shown valve reoperation rates are higher for tissue valves used in these younger participants. Providing an alternative to warfarin anticoagulation may lead younger participants to choose a mechanical valve with greater durability and better clinical outcomes.

03

Conditions studied

  • Aortic Valve Disease
  • Aortic Valve Stenosis
  • Aortic Valve Failure

Browse trials for

04

In context

Aortic Valve Stenosis Reclassified

1,026 studies on the registry are indexed under Aortic Valve Stenosis; 294 are open to participants now.

This study's enrollment of 863 is above the median of 126 across 554 interventional studies indexed under Aortic Valve Stenosis.

Browse Aortic Valve Stenosis studies →

Lead sponsor

Artivion Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Compared within Aortic Valve Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Valve Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 18 years of age at the time of giving .
  • Participants currently receiving warfarin anticoagulation and who are able to receive warfarin with a target 2.0 to 3.0.
  • Participants are able to take low-dose aspirin at a dose of 75 -100 mg daily or have a documented to aspirin use.
  • Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
  • Female participants of , including those who are less than 2 years , must agree to, and comply with using a highly effective method of (eg, barrier contraceptives [condom or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices or sexual abstinence) while partaking in this study. In addition, all women of childbearing potential must agree to continue to use birth control throughout the study until last study visit.
  • Informed of the full nature and purpose of the study, including possible risks and side effects, given ample time and opportunity to read and understand this information, and sign and date the written informed consent before inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • Mechanical valve in any position other than aortic valve.
  • Any cardiac surgery in the three months (90 days) prior to enrollment.
  • Need to be on aspirin >100 mg daily or a P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel, or ticlopidine).
  • Known or other to apixaban.
  • On dialysis or a \< 25 mL/min.
  • Ischemic stroke or intracranial hemorrhage within 3 months.
  • Active pathological bleeding at the time of screening for enrollment.
  • Active endocarditis at the time of screening for enrollment.
  • Pregnant, plan to become pregnant, or are breast feeding.
  • On concomitant combined strong P-gp and inducers or inhibitors.
  • History of non-compliance with recommended monthly testing.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
863 participants (actual)

Study arms

  • Experimental
    Apixaban

    Apixaban 5 mg twice daily(BID) or 2.5 mg BID

    Drug: Apixaban 5 MG · Drug: Apixaban 2.5 MG · Device: On-X Aortic Mechanical Valve

  • Active comparator
    Warfarin

    Patients randomized to the warfarin arm will continue warfarin in the INR range of (2.0-3.0)

    Drug: Warfarin · Device: On-X Aortic Mechanical Valve

Interventions

  • For patients that do NOT meet the following criteria * age ≥ 80 years * weight ≤ 60 kilograms * creatinine ≥ 1.5 mg/dL (133 micromol/L)

  • For patients that meet at least 2 of the following criteria * age ≥ 80 years * weight ≤ 60 kilograms * creatinine ≥ 1.5 mg/dL (133 micromol/L)

  • Active Control Intervention

  • DeviceOn-X Aortic Mechanical Valve

    Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.

    Also known as: On-X Ascending Aortic Prosthesis (AAP)

07

What researchers measure

Primary outcomes

  1. Composite of Valve Thrombosis and Valve-related Thromboembolism

    Valve thrombosis was defined as any thrombus, not caused by infection, attached to or near an implanted On-X valve that occluded part of the blood-flow path, interfered with valve function, or was sufficiently large to warrant treatment other than continued oral anticoagulation. Valve-related thromboembolism was defined as any thromboembolic stroke, transient ischemic attack, myocardial infarction, or arterial thromboembolism to an organ or limb that was not associated with infection or an intracardiac tumor and was definitely or possibly related to the valve.

    Time frame: through study closure, a median follow-up of 13.5 months

  2. Major Bleeding

    Major bleeding defined as any episode of internal or external bleeding that caused death, hospitalization, or permanent injury or necessitated transfusion, pericardiocentesis, or reoperation.

    Time frame: through study closure, a median follow-up of 13.5 months

08

Results

Posted Mar 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneApixabanWarfarin
Started433430
Completed418400
Not completed1530
Withdrew: Death21
Withdrew: Lost to follow-up413
Withdrew: Withdrawal by subject916

Outcome measures

PrimaryComposite of Valve Thrombosis and Valve-related Thromboembolism

Valve thrombosis was defined as any thrombus, not caused by infection, attached to or near an implanted On-X valve that occluded part of the blood-flow path, interfered with valve function, or was sufficiently large to warrant treatment other than continued oral anticoagulation. Valve-related thromboembolism was defined as any thromboembolic stroke, transient ischemic attack, myocardial infarction, or arterial thromboembolism to an organ or limb that was not associated with infection or an intracardiac tumor and was definitely or possibly related to the valve.

Time frame:
through study closure, a median follow-up of 13.5 months
Reported as:
Number · events per patient-years
Composite of Valve Thrombosis and Valve-related Thromboembolism
events per patient-yearsApixabanWarfarin
Composite of Valve Thrombosis and Valve-related Thromboembolism206
PrimaryMajor Bleeding

Major bleeding defined as any episode of internal or external bleeding that caused death, hospitalization, or permanent injury or necessitated transfusion, pericardiocentesis, or reoperation.

Time frame:
through study closure, a median follow-up of 13.5 months
Reported as:
Number · event
Major Bleeding
eventApixabanWarfarin
Major Bleeding1721

Adverse events

Collected over through study closure, a median follow-up of 13.5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban2/433 (0.5%)11/433 (2.5%)16/433 (3.7%)
Warfarin1/430 (0.2%)18/430 (4.2%)6/430 (1.4%)
Most frequent serious events
Most frequent serious events
EventApixabanWarfarin
Major BleedingSurgical and medical procedures11/43318/430
Most frequent other events
Most frequent other events
EventApixabanWarfarin
Valve thrombosis or Valve-related thromboembolismSurgical and medical procedures16/4336/430

Baseline characteristics

Age, Customized
Age, Customized(years)ApixabanWarfarinTotal
Median56 (47 to 63)55 (47 to 63)56 (47 to 63)
Sex: Female, Male
Sex: Female, Male(Participants)ApixabanWarfarinTotal
Female102105207
Male331325656
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ApixabanWarfarinTotal
Hispanic or Latino292049
Not Hispanic or Latino400406806
Unknown or Not Reported448
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ApixabanWarfarinTotal
American Indian or Alaska Native033
Asian358
Black or African American81422
Native Hawaiian or Other Pacific Islander123
White395390785
Multiracial202
Other7310
Unknown171330
BMI
BMI(kg/m^2)ApixabanWarfarinTotal
Median29.9 (26.3 to 34.3)30.1 (26.3 to 35.0)29.9 (26.3 to 34.6)
09

Study locations

62 sites
  • Tucson Heart Center
    Tucson, Arizona 85712, United States
  • CHI St. Vincent Heart Institute
    Little Rock, Arkansas 72205, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • Stanford University Medical Center
    Palo Alto, California 94305, United States
  • Sharp Memorial
    San Diego, California 92123, United States
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Yale- New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Baycare Health / Morton Plant Hospital
    Clearwater, Florida 33756, United States
  • Shands Hospital (University of Florida Health)
    Gainesville, Florida 32608, United States
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
  • Tallahassee Research Institute
    Tallahassee, Florida 32308, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Emory University Hospital
    Atlanta, Georgia 30332, United States
  • Northeast Georgia Medical Center
    Gainesville, Georgia 30501, United States
  • Wellstar Kennestone Hospital
    Marietta, Georgia 30060, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • OSF Cardiovascular Institute
    Rockford, Illinois 61107, United States
  • Indiana University Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
  • Franciscan Health Indianapolis
    Indianapolis, Indiana 46237, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • John's Hopkins University
    Baltimore, Maryland 21218, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Michigan Health
    Ann Arbor, Michigan 48109, United States
  • Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
  • University of Minnesota
    Minneapolis, Minnesota 55422, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55902, United States
  • Saint Luke's Hospital
    Kansas City, Missouri 64111, United States
  • Washington University Medical Center
    Saint Louis, Missouri 63105, United States
  • Missouri Baptist Medical Center
    Saint Louis, Missouri 63131, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Mount Sinai- St. Luke's Hospital
    New York, New York 10029, United States
  • NewYork-Presbyterian Hospital
    New York, New York 10065, United States
  • NewYork-Presbyterian/ Weill Cornell Medical Center
    New York, New York 10065, United States
  • Vassar Brothers Medical Center
    Poughkeepsie, New York 12601, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Atrium Health Carolinas Medical Center (CMC)
    Charlotte, North Carolina 28203, United States
  • Duke University
    Durham, North Carolina 27708, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • ProMedica Toledo Hospital
    Toledo, Ohio 43606, United States
  • Oklahoma Heart Hospital
    Oklahoma City, Oklahoma 73120, United States
  • Lehigh Valley Hospital Allentown
    Allentown, Pennsylvania 18103, United States
  • Penn State Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • UPMC Shadyside
    Pittsburgh, Pennsylvania 15232, United States
  • Avera Health / North Central Heart
    Sioux Falls, South Dakota 57108, United States
  • Tristar Centennial Medical Center
    Nashville, Tennessee 37203, United States
  • William P. Clements Jr. University Hospital
    Dallas, Texas 75235, United States
  • TCU School of Medicine
    Fort Worth, Texas 76107, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • The Heart Hospital at Baylor Plano
    Plano, Texas 75093, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • Henrico Doctors' Hospital
    Richmond, Virginia 23229, United States
  • Carilion Roanoke Memorial Hospital
    Roanoke, Virginia 24014, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Tacoma General Hospital
    Tacoma, Washington 98405, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Wauwatosa, Wisconsin 53226, United States
10

References and documents

Publications

  • Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL, Takkenberg JJ, David TE, Butchart EG, Adams DH, Shahian DM, Hagl S, Mayer JE, Lytle BW; Councils of the American Association for Thoracic Surgery; Society of Thoracic Surgeons; European Assoication for Cardio-Thoracic Surgery; Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg. 2008 Apr;135(4):732-8. doi: 10.1016/j.jtcvs.2007.12.002. No abstract available. PubMed 18374749 ↗
  • Bourguignon T, Lhommet P, El Khoury R, Candolfi P, Loardi C, Mirza A, Boulanger-Lothion J, Bouquiaux-Stablo-Duncan AL, Marchand M, Aupart M. Very long-term outcomes of the Carpentier-Edwards Perimount aortic valve in patients aged 50-65 years. Eur J Cardiothorac Surg. 2016 May;49(5):1462-8. doi: 10.1093/ejcts/ezv384. Epub 2015 Nov 2. PubMed 26530269 ↗
  • Chambers JB, Pomar JL, Mestres CA, Palatianos GM. Clinical event rates with the On-X bileaflet mechanical heart valve: a multicenter experience with follow-up to 12 years. J Thorac Cardiovasc Surg. 2013 Feb;145(2):420-4. doi: 10.1016/j.jtcvs.2011.12.059. Epub 2012 Feb 17. PubMed 22341654 ↗
  • Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. doi: 10.1056/NEJMoa1300615. Epub 2013 Aug 31. PubMed 23991661 ↗
  • Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50-69 years. Eur Heart J. 2016 Sep 7;37(34):2658-67. doi: 10.1093/eurheartj/ehv580. Epub 2015 Nov 11. PubMed 26559386 ↗
  • Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, Woo YJ. Mechanical or Biologic Prostheses for Aortic-Valve and Mitral-Valve Replacement. N Engl J Med. 2017 Nov 9;377(19):1847-1857. doi: 10.1056/NEJMoa1613792. PubMed 29117490 ↗
  • Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. PubMed 21870978 ↗
  • Head SJ, Mylotte D, Mack MJ, Piazza N, van Mieghem NM, Leon MB, Kappetein AP, Holmes DR Jr. Considerations and Recommendations for the Introduction of Objective Performance Criteria for Transcatheter Aortic Heart Valve Device Approval. Circulation. 2016 May 24;133(21):2086-93. doi: 10.1161/CIRCULATIONAHA.115.020493. PubMed 27217434 ↗
  • Head SJ, Celik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J. 2017 Jul 21;38(28):2183-2191. doi: 10.1093/eurheartj/ehx141. PubMed 28444168 ↗
  • IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014 Feb 18;14:25. doi: 10.1186/1471-2288-14-25. PubMed 24548571 ↗
  • Samsa G, Matchar DB, Dolor RJ, Wiklund I, Hedner E, Wygant G, Hauch O, Marple CB, Edwards R. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes. 2004 May 6;2:22. doi: 10.1186/1477-7525-2-22. PubMed 15132746 ↗
  • Lester PA, Coleman DM, Diaz JA, Jackson TO, Hawley AE, Mathues AR, Grant BT, Knabb RM, Ramacciotti E, Frost CE, Song Y, Wakefield TW, Myers DD Jr. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. Arterioscler Thromb Vasc Biol. 2017 May;37(5):942-948. doi: 10.1161/ATVBAHA.116.308649. Epub 2017 Feb 23. PubMed 28232327 ↗
  • McNicholas KW, Ivey TD, Metras J, Szentpetery S, Marra SW, Masters RG, Dilling EW, Slaughter MS, Mack MJ. North American multicenter experience with the On-X prosthetic heart valve. J Heart Valve Dis. 2006 Jan;15(1):73-8; discussion 79. PubMed 16480015 ↗
  • Palatianos GM, Laczkovics AM, Simon P, Pomar JL, Birnbaum DE, Greve HH, Haverich A. Multicentered European study on safety and effectiveness of the On-X prosthetic heart valve: intermediate follow-up. Ann Thorac Surg. 2007 Jan;83(1):40-6. doi: 10.1016/j.athoracsur.2006.08.010. PubMed 17184628 ↗
  • Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, Fermin L, McGrath M, Kong B, Hughes C, Sethi G, Wait M, Martin T, Graeve A; PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014 Apr;147(4):1202-1210; discussion 1210-1. doi: 10.1016/j.jtcvs.2014.01.004. Epub 2014 Jan 12. PubMed 24512654 ↗
  • Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D, Copeland J, Quinn R, Hughes GC, Azar H, McGrath M, Wait M, Kong B, Martin T, Douville EC, Meyer S, Ye J, Jamieson WRE, Landvater L, Hagberg R, Trotter T, Armitage J, Askew J, Accola K, Levy P, Duncan D, Yanagawa B, Ely J, Graeve A; PROACT Investigators. Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. J Am Coll Cardiol. 2018 Jun 19;71(24):2717-2726. doi: 10.1016/j.jacc.2018.03.535. PubMed 29903344 ↗
  • Tossios P, Reber D, Oustria M, Holland-Letz T, Germing A, Buchwald D, Laczkovics A. Single-center experience with the On-X prosthetic heart valve between 1996 and 2005. J Heart Valve Dis. 2007 Sep;16(5):551-7. PubMed 17944128 ↗
  • Williams MA, van Riet S. The On-X heart valve: mid-term results in a poorly anticoagulated population. J Heart Valve Dis. 2006 Jan;15(1):80-6. PubMed 16480016 ↗
  • Wu Y, Butchart EG, Borer JS, Yoganathan A, Grunkemeier GL. Clinical evaluation of new heart valve prostheses: update of objective performance criteria. Ann Thorac Surg. 2014 Nov;98(5):1865-74. doi: 10.1016/j.athoracsur.2014.05.006. Epub 2014 Sep 23. PubMed 25258160 ↗
  • Jawitz OK, Wang TY, Lopes RD, Chavez A, Boyer B, Kim H, Anstrom KJ, Becker RC, Blackstone E, Ruel M, Thourani VH, Puskas JD, Gerdisch MW, Johnston D, Capps S, Alexander JH, Svensson LG. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. Am Heart J. 2020 Sep;227:91-99. doi: 10.1016/j.ahj.2020.06.014. Epub 2020 Jun 25. PubMed 32693197 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Dec 2022, 31 months.

Results were first posted in Mar 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2019
First posted
Oct 29, 2019
StartActual
May 1, 2020
Primary completionActual
Dec 12, 2022
CompletionActual
Dec 12, 2022
Results first posted
Mar 20, 2024
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04142658
Lead sponsor
Artivion Inc.
Collaborators
Duke Clinical Research Institute
Responsible party
Sponsor
First posted
Oct 29, 2019
Start date
May 1, 2020
Primary completion
Dec 12, 2022
Completion
Dec 12, 2022
Results posted
Mar 20, 2024
Last update
Mar 20, 2024

Study contacts

Lars Svensson, MD, PhD
study chair · Steering Committee
John Alexander, MD
study chair · Steering Committee

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion